BBK Worldwide is introducing a Patient Recruitment Franchise Program. BBK’s flagship product for its new program is the FRANCHISE e-BINDERSM: a communication platform that uses the Apple iPad® to facilitate the myriad processes necessary to effectively recruit and manage patients for global clinical trials.
This new franchise model supports quick, efficient enrollment for multiple studies within the same therapeutic category, as well as multiple protocols for a single compound. “Franchise programs create savings through the economies of scale derived from applying strategies and tactics across multiple studies and countries,” said Joan F. Bachenheimer, BBK Worldwide founding principal and CEO. “Using the model of the Patient Recruitment Franchise Program, sponsors are able to consolidate planning and recruitment strategies for immediate and long-term cost reductions.”
The Apple iPad supports franchise-level initiatives by making it possible to instantly distribute, store, and retrieve information and data with the tap of a finger. “BBK’s application of this new technology skillfully supports clinical research professionals as they work to manage the avalanche of information surrounding clinical trial particulars,” said Matthew Stumm, BBK Worldwide creative director. Consider the following audience-specific applications of the FRANCHISE e-BINDER, powered by BBK partner company TCN e-Systems:
· Investigator meetings made simple
· Top-level data sourced and easily retrieved for clinical operations
· The STUDY MANAGER e-BINDERSM offers one-stop access to critical forms, inclusion/exclusion criteria, patient materials, etc.Can be adapted for any country/language.
· The UPDATE e-BINDERSM for clinical study managers and monitors provides a hand-held portal to site administration resources – including training, study contact listings, sponsor documentation, clinical assessment tools
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.